In the last decade, numerous studies have revealed that antagonists that block the direct adenosine-generating enzyme CD73 and the adenosine receptors A2AR or A2BR in cancer have a strong anti-tumor effect by restricting the adenosine-induced immune-suppressive microenvironment [90–93]. Here, NT5E is linked to cancer.